Key Takeaways from Guggenheim's 2026 Boston BioFrontier Meetings

Research evidence excerpt

Key Takeaways from Guggenheim's 2026 Boston BioFrontier Meetings

Global Biopharmaceuticals June 29, 2026

Guggenheim Therapeutics Research

GStherapeutics@guggenheimpartners.com Key Takeaways from Guggenheim's 2026 Boston

Brad Canino BioFrontier Meetings brad.canino@guggenheimpartners.com

212 823 6558

Key Message: Last week, we held our 2026 BioFrontier Boston event, where we visited Debjit Chattopadhyay, Ph.D.

debjit.chattopadhyay@guggenheimpartners.com and/or hosted 24 companies across our pharma and biotech coverage universe. Here

212 823 6584 we share our key takeaways from our conversations with biotech management teams.

Vamil Divan, M.D.

vamil.divan@guggenheimpartners.com Adicet Bio (ACET: Suneja) Chen Schor, CEO & President

ACET has previously announced early 212 823 6543 • Prula-cel (allogeneic γδ CAR-T) in LN/SLE:

Seamus Fernandez LN/SLE data in 7 patients (5 LN, 2 SLE) showing complete depletion of CD19+ B

seamus.fernandez@guggenheimpartners.com cells in circulation and reconstitution of naive B cells. In LN, 3/5 patients had complete

617 859 4637 renal responses and the other 2/5 achieved partial responses, with patients stopping

Michael Schmidt, Ph.D. other immunosuppressants and with steroids tapering to zero or <5 mg prednisolone

michael.schmidt@guggenheimpartners.com equivalent. The upcoming dataset is expected in mid-2026 and will include >20 patients

617 859 4636 with 6-12-month follow-up, per management - positioning it as the largest allogeneic cell

Yatin Suneja therapy dataset in LN/SLE (and SSc) to date, comparable in size to NOVN-SWX's and

yatin.suneja@guggenheimpartners.com BMY's CAR-T datasets. For the future pivotal study, ACET anticipates a single-arm LN

212 518 9565 trial of similar scale to competitors, with potential expansion to SLE.